CHICAGO, April 15, 2024 /PRNewswire/ -- Synapticure, a leading telemedicine company focused on improving the lives of people and caregivers living with neurodegenerative diseases, and the ALS Association, the leading organization fighting ALS, announced a new partnership to expand access to quality care for people living with ALS across the United States.
Through this collaboration, the ALS Association will offer Synapticure's innovative telemedicine platform to supplement in-person visits at ALS Certified Treatment Centers of Excellence and Recognized Treatment Centers. This will be particularly beneficial for people living with ALS in geographically remote areas who may struggle to access specialized multidisciplinary care. Additionally, Synapticure's asynchronous model allows for flexible scheduling and remote monitoring, further easing the burden on people living with ALS and their families.
"We are thrilled to partner with Synapticure to offer this innovative telehealth solution to people living with ALS nationwide. This collaboration will help us bridge the gap in access to specialized care, ensuring people living with ALS receive the comprehensive support they deserve," said Kimberly Maginnis, senior vice president, care services.
As part of this collaboration, the ALS Association will provide people living with ALS access to both local and national resources. A designated ALS Association patient liaison will be embedded within the Synapticure virtual clinic to help navigate the healthcare landscape and help provide personalized support to the care they need.
"Our mission at Synapticure is focused on providing state-of-the-art care regardless of geography. In partnership with the ALS Association, harnessing our combined national reach and deep expertise will enable us to revolutionize what it means to truly serve the ALS population. Working together, we will set a new standard of virtual care delivery," said Sandra Abrevaya, CEO and co-founder of Synapticure.
Synapticure exists to provide accessible, compassionate care to patients and caregivers impacted by neurodegenerative diseases, having first launched in ALS. Enabled by telehealth, Synapticure has a multidisciplinary team that includes care coordinators, specialized neurologists, neuropsychologists, speech and language therapists, genetic counselors, insurance navigators, and more. Synapticure's team supports patients and caregivers living with neurodegenerative conditions, like ALS, to optimize available insurance benefits, access mental health support through our behavioral health team, obtain genetic testing and counseling, schedule in-home PT/OT, and provide expert guidance related to clinical trials, expanded access programs, and supplements.
Benefits of the partnership will include:
About the ALS Association
The ALS Association is the largest ALS organization in the world. The ALS Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association is working to make ALS a livable disease while urgently searching for new treatments and a cure. For more information about the ALS Association, visit our website at www.als.org.
About Synapticure
Synapticure is dedicated to creating the future of neurodegenerative disease patient care. Today, Synapticure is focused on providing better treatment and care for all people living with ALS through a full-stack teleneurology platform, built by and for those living with ALS. Co-founded by Brian Wallach, Sandra Abrevaya, Peter Wallach, Jason Langheier and Jonathan Hirsch, Synapticure is headquartered in Chicago, Illinois. To learn more, please visit synapticure.com or follow us on Twitter, LinkedIn, Facebook, and Instagram for updates.
About ALS
ALS is 100% fatal and affects more than 30,000 people in the U.S. The lifetime risk of developing ALS is 1 in 300, the same as Multiple Sclerosis. Each year, more than five thousand people are diagnosed with ALS in the US alone. This number is expected to nearly double by 2060. People living with ALS, on average, live two to five years after diagnosis, and nearly half live more than 50 miles away from the closest ALS multidisciplinary clinic.
About Parkinson’s Disease
Parkinson's disease is a progressive neurodegenerative disease that causes nerve cells (or neurons) in the area of the brain that controls movement to weaken and/or die. More than 10 million people worldwide are currently living with Parkinson's disease. The number of people diagnosed with with Parkinson’s Disease is expected to rise from 900,000 to 1.2 million by 2030. What causes Parkinson's remains largely unknown. Genetics cause about 10 to 15 percent of all Parkinson's. The other 85 to 90 percent of cases are classified as sporadic (or occasional). Although there is no cure, treatment options vary and include medications and surgery.
